Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.
In the 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists, a compound containing an imidazopyridine arginine mimetic was discovered which had sufficient potency and i.v. pharmacokinetics for demonstration of efficacy in a rat restenosis model.
Keenan
R M
RM
Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA.
Lago
M A
MA
Miller
W H
WH
Ali
F E
FE
Cousins
R D
RD
Hall
L B
LB
Hwang
S M
SM
Jakas
D R
DR
Kwon
C
C
Louden
C
C
Nguyen
T T
TT
Ohlstein
E H
EH
Rieman
D J
DJ
Ross
S T
ST
Samanen
J M
JM
Smith
B R
BR
Stadel
J
J
Takata
D T
DT
Vickery
L
L
Yuan
C C
CC
Yue
T L
TL
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000818:Animals; D001569:Benzodiazepines / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004195:Disease Models, Animal; D007093:Imidazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors*
D007093:Imidazoles; D011725:Pyridines; D019030:Receptors, Vitronectin; D001569:Benzodiazepines